CHP
TEVA icon

Cable Hill Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Cable Hill Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-380
Closed -$7K – 1011
2017
Q3 		$7K Sell
380
-100
-21% -$2.25K ﹤0.01% 688
2017
Q2 		$16K Sell
480
-441
-48% -$13.7K 0.01% 304
2017
Q1 		$29K Buy
921
+397
+76% +$13.5K 0.02% 209
2016
Q4 		$19K Sell
524
-404
-44% -$16.1K 0.01% 274
2016
Q3 		$42K Hold
928
– – 0.03% 171
2016
Q2 		$48K Hold
928
– – 0.04% 132
2016
Q1 		$51K Sell
928
-300
-24% -$17.6K 0.04% 113
2015
Q4 		$81K Buy
1,228
+300
+32% +$18.5K 0.06% 85
2015
Q3 		$56K Sell
928
-50
-5% -$3.24K 0.04% 121
2015
Q2 		$61K Sell
978
-300
-23% -$18.5K 0.05% 117
2015
Q1 		$80K Sell
1,278
-50
-4% -$2.91K 0.06% 88
2014
Q4 		$77K Buy
+1,328
New +$74K 0.08% 92

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

Cable Hill Partners's TEVA Position: Q4 2017 in Review

Cable Hill Partners sold out of Teva Pharmaceuticals (TEVA) in Q4 2017, closing a stake of 380 shares — an estimated $7K sold.

Cable Hill Partners first reported a position in TEVA in Q4 2014 and held it in 12 quarters. The position peaked at $81K in Q4 2015. 507 funds tracked by Wall St. Rank hold TEVA as of Q4 2017.

  • Cable Hill Partners reported no remaining Teva Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Cable Hill Partners sold 380 Teva Pharmaceuticals shares in Q4 2017, an estimated $7K.
  • Cable Hill Partners first reported a position in Teva Pharmaceuticals in Q4 2014 and held it in 12 quarters.
  • Cable Hill Partners's Teva Pharmaceuticals position peaked at $81K in Q4 2015.
  • 507 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2017.

Based on Cable Hill Partners's 13F filing for Q4 2017, filed 22 Feb 2018.